Search - tctmd.com

Displaying 361 - 380 of 440

Sort: Relevancy | Date

News Industry News

Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart Procedures

August 01, 2017

TCTMD’s Top 10 Most Popular Stories for July 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

July 31, 2017

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

June 16, 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke

News Daily News

Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke

May 24, 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

News Conference News EuroPCR 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

Yael L. Maxwell

May 17, 2017

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

News Daily News

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

May 17, 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

May 12, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

News Conference News ACC 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

March 19, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.